<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862537</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.583</article-id><article-id pub-id-type="other">EPP0434</article-id><article-id pub-id-type="pii">S0924933824005832</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Features of the spectrum of immune markers in patients with juvenile depression with clinically high risk of psychosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Zozulya</surname><given-names>S. A.</given-names></name><xref rid="aff1349" ref-type="aff"/><xref rid="cor0444" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Omelchenko</surname><given-names>M. A.</given-names></name><xref rid="aff1349" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Otman</surname><given-names>I. N.</given-names></name><xref rid="aff1349" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Sarmanova</surname><given-names>Z. V.</given-names></name><xref rid="aff1349" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Migalina</surname><given-names>V. V.</given-names></name><xref rid="aff1349" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Kaleda</surname><given-names>V. G.</given-names></name><xref rid="aff1349" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Klyushnik</surname><given-names>T. P.</given-names></name><xref rid="aff1349" ref-type="aff"/></contrib></contrib-group><aff id="aff1349">
<institution>Mental Health Research Centre</institution>, <city>Moscow</city>, <country>
Russian Federation</country>
</aff><author-notes><corresp id="cor0444">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="558">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S279</fpage><lpage>S279</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824005832a.pdf"/><abstract><sec id="sec2666"><title>Introduction</title><p>Identification of biomarkers associated with the risk of psychosis manifestation in juvenile patients with depression may contribute to a better understanding of the pathogenesis of mental disorders and early diagnosis.</p></sec><sec id="sec2667"><title>Objectives</title><p>To determine the level of pro-inflammatory and anti-inflammatory cytokines and other inflammatory indicators in the plasma of juvenile patients with depression and clinically high risk of psychosis, and to study the correlation of these markers with the severity of psychopathologic symptoms.</p></sec><sec id="sec2668"><title>Methods</title><p>80 young men aged 16-24 years with the first depressive episode (F32.1-2, F32.38, F32.8) were examined. Based on the severity of attenuated psychotic symptoms (APS) in the structure of depression according to the SOPS scale, all patients were divided into two groups - with clinically high risk of psychosis (n=58) and with depression without APS (n=22). The HDRS-21 and SANS scales were also used for psychometric assessment. Serum level of cytokines TNF-&#x003b1;, IL-6, IL-8, IL-10, TNF-&#x003b1;/IL-6 ratio, TNF-&#x003b1;/IL-10 ratio, leukocyte elastase (LE) and &#x003b1;1-proteinase inhibitor (&#x003b1;1-PI) activity, C-reactive protein (CRP) concentration, and the level of autoantibodies to S-100B protein were determined.</p></sec><sec id="sec2669"><title>Results</title><p>Both groups of patients showed a high level of inflammation assessed by LE and &#x003b1;1-PI activity (p&#x0003e;0.05). Significantly higher level of IL-6 (p=0.03), CRP concentration (p=0.026) and TNF-&#x003b1;/IL-10 ratio (p=0.032) were found in patients with clinically high risk of psychosis. This group was also characterised by high level of autoantibodies to the S-100B protein compared to patients with depression without APS (p=0.048).</p><p>
In the high clinical risk group, correlations were found between the SOPS positive subscale score and the level of TNF-&#x003b1; (R=0.32, p=0.017), IL-8 (R=-0.3, p=0.034), TNF-&#x003b1;/IL-6 ratio (R=0.30, p=0.021) and TNF-&#x003b1;/IL-10 ratio (R=0.32, p=0.014). The SOPS negative subscale score correlated with CRP concentration (R=0.3, p=0.043). The SOPS total score correlated with TNF-&#x003b1;/IL-10 ratio (R=0.31, p=0.021). In this group of patients, the level of IL-10 was found to correlate with the duration of the disease (R=0.48, p&#x0003c;0.001). In patients with depression without APS, the level of IL-6 was correlated with the severity of depression according to the HDRS scale, and the level of TNF-&#x003b1; was associated with the duration of the depressive episode (R=0.51, p=0.029).</p></sec><sec id="sec2670"><title>Conclusions</title><p>The obtained results confirm the involvement of inflammation in the development of juvenile depression. Qualitative and quantitative characteristics of the spectrum of immune markers and the cytokine profile, and correlations with the severity of psychopathologic symptoms were revealed in patients with clinically high risk of psychosis.</p></sec><sec id="sec2671"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>